Clinical trials: Venous Thromboembolic Event
VTE (Venous Thromboembolism)
AQT90 FLEX D-dimer Clinical Sensitivity and Specificity
The goal of this study is evaluate the clinical performance of the AQT90 FLEX D-dimer Test as an aid in the diagnosis of Venous Thromboembolism.
- Trial name
- NCT06749223
- Testing
- D-dimer test
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Radiometer Medical ApS
Venous Thromboembolism
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.
- Trial name
- NCT00689520
- Testing
- tinzaparin, acenocoumarol
- Where
- 2 sites in Spain
- Volunteers
- 241 people
- Sponsor
- Hospital Universitari de Bellvitge
Venous Thromboembolism, Arthroplasty
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT)…
- Trial name
- NCT05449327
- Testing
- Rivaroxaban 10 MG
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Chiayi Christian Hospital
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate in Adolescents
To investigate the safety and tolerability of dabigatran etexilate capsules in a small group of eight adolescent patients.
- Trial name
- NCT00844415
- Testing
- dabigatran etexilate
- Where
- 2 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism (VTE)
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection
A phase 1 study to evaluate the safety and tolerability of a single administration of YKYY033 injection in healthy adult participants
- Trial name
- NCT07786779
- Testing
- YKYY033 Injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism
Thrombosis Outcomes in Pediatric Venous Thromboembolism
'The TOP Study' is a prospective cohort study whose main objective is to develop better prognostic biomarkers and identify children at risk of adverse thrombotic outcomes very early in the course after an initial venous…
- Trial name
- TOP (NCT03068923)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
- Trial name
- NCT07856641
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Arterial Thromboembolism, Venous Thromboembolism
Aspiration Thrombectomy Using the Symphony or Prodigy System
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- CLEAR-IT (NCT07350499)
- Testing
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Where
- 13 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Thromboses, Venous, Lower Limb Injury
A Prospective Study to Assess the Risk Factors That Contribute to Thrombosis in Patients With Lower Limb Injuries.
This study is aimed at identifying patients at high risk for Venous Thrombo-Embolism (VTE) (clots in the veins of legs or clots in the lungs) who have lower limb injuries treated with immobilisation of the lower limb.
- Trial name
- TILLIRI (NCT04608591)
- Where
- Ireland
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- University of Limerick
Postpartum Period, Cesarean Section Surgery
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
Pregnancy and the postpartum period increase venous thromboembolism (VTE) risk. After cesarean section, low-molecular-weight heparin (LMWH; enoxaparin) is commonly used for short-term thromboprophylaxis, but it requires daily…
- Conditions
- Postpartum Period, Cesarean Section Surgery, VTE (Venous Thromboembolism)
- Trial name
- NCT07820670
- Testing
- Rivaroxaban, Enoxaparin 40 mg
- Where
- Israel
- Volunteers
- 62 people
- Sponsor
- Wolfson Medical Center
Placental Vascular Pathologies, Venous Thromboembolism Diseases
Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease
Venous thromboembolic (VTE) disease is the first cause of maternal mortality in the world. Some other pregnancy pathologies called Placental Vascular Pathologies (PVP) are linked to VTE by biological thrombophilia and are the…
- Trial name
- AngioPred (NCT00695942)
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Survey, Venous Thromboembolism
Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
In France, venous thromboembolic (VTE) disease is usually managed by vascular medicine physicians (VMP). The national OPTIMEV study, conducted more than 12 years ago among VMP practicing in hospital and in the community described…
- Conditions
- Survey, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- Observ-MTEV (NCT04272723)
- Where
- France
- Volunteers
- 383 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Cerebral Venous Thrombosis
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
Rationale: Patients with cerebral venous thrombosis (CVT) are currently treated with anticoagulants during 3-12 months after diagnosis, to prevent worsening of the CVT and recurrent thrombosis, and to promote venous…
- Trial name
- DOAC-CVT (NCT04660747)
- Testing
- Oral anticoagulant
- Where
- Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thromboembolism
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland
Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated.
- Trial name
- NCT01277536
- Where
- 7 sites in Switzerland
- Volunteers
- 1,478 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolic Disease
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation.
- Trial name
- QuantiXa (NCT05993533)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Brain Infarction, Ischemic Stroke
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes occur at younger ages. Stroke at young age causes marked disability at worst and thus long-standing socioeconomic consequences and…
- Conditions
- Brain Infarction, Ischemic Stroke, Thrombosis, Foramen Ovale, Patent
- Trial name
- SECRETO (NCT01934725)
- Where
- 19 sites in Estonia, Finland and 11 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- SECRETO Study Consortium